Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
|Articles|September 18, 2014
- Melanoma (Issue 3)
- Volume 3
- Issue 1
Immunotherapy Combinations for the Treatment of Melanoma
Author(s)Mario Sznol, MD
Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses the potential for immunotherapy combinations for the treatment of melanoma.
Advertisement
Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses the potential for immunotherapy combinations for the treatment of melanoma.
Read about checkpoint strategies for the treatment of melanoma > >
Articles in this issue
about 12 years ago
Inducing an Immune Response With a Patient’s Tumorabout 12 years ago
Partnering T-VEC With a Targeted Agent for the Treatment of MelanomaAdvertisement
Related to this article
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5